hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06287957, orgStudyIdInfo id: IU-DHF-AG-01, briefTitle: Chitosan Brushes vs Air-Abrasive Devices on Peri-implant Mucositis Treatment: A Randomized Clinical, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2025-02-15, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Istanbul University, class: OTHER, descriptionModule briefSummary: Bleeding on probing (0,1,2,3), plaque index (+,-) and pocket probing depth will be recorded for each visit. Before the procedure, the patient will be randomly assigned to one of four groups and records will be kept. In the frst visit of the patient, necessary actions will be taken according to the group to which the patient is assigned. The implant periphery of the patients assigned to the chitosan brush group will be debrided with a chitosan brush with circular movements. The implants of the patients assigned to the air abrasive device group will be cleaned in the same way with circular movements. The debrided area of both groups will be washed with sterile serum after the treatment. Patients will be called at the 2nd, 4th and 12th weeks and compared with the records kept., conditionsModule conditions: Peri-implant Mucositis, conditions: Peri-Implantitis, conditions: Bleeding on Probing, conditions: Periodontal Pocket, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: There are going to be 4 treatment groups. Group 1: Mini Implant Platform treated with Labrida Bioclean Group 2: Regular Implant Platform treated with Labrida Bioclean Group 3: Mini Implant Platform treated with Air-Flow Device Group 4: Regular Implant Platform treated with Air-Flow Device, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Labrida BioClean, interventions name: EMS Handy 3.0 Perio Premium, outcomesModule primaryOutcomes measure: Probing Depth, secondaryOutcomes measure: Bleeding on Probing, otherOutcomes measure: Plaque Index, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul University, status: RECRUITING, city: Istanbul, state: Fatih, zip: 34080, country: Turkey, contacts name: Alper Gultekin, Assistant Professor, role: CONTACT, phone: +90 5326757236, email: alperg@istanbul.edu.tr, contacts name: Kerem Bahceci, PhD Candidate, role: CONTACT, phone: +90 5317132633, email: kerembhc@gmail.com, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06287931, orgStudyIdInfo id: sdllycyy001, briefTitle: Probiotics for Gallstones in Post-bariatric Surgery Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Shandong Linglong Yingcheng Hospital, class: NETWORK, descriptionModule briefSummary: Obesity is an increasing epidemic worldwide and has a significant impact on human health and socioeconomics. Multiple studies have shown that bariatric surgery increases the risk of postoperative gallbladder stones. Contributing factors to gallstone formation include gallbladder motility and bile supersaturation due to rapid weight loss and cholesterol mobilization. At present, the prevention and treatment of gallbladder stones in obese patients after bariatric surgery are still controversial. In recent years, the study of ursodeoxycholic acid in preventing gallbladder stone formation after bariatric surgery has become a research hotspot. At the same time, other studies have shown that taking probiotics or digestive enzymes may improve gastrointestinal symptoms and improve quality of life after bariatric surgery. Therefore, the purpose of this study was to determine the ability of probiotics to prevent gallstone formation after bariatric surgery and to evaluate the impact of oral probiotics on quality of life in patients after bariatric surgery., conditionsModule conditions: Bariatric Surgery Candidate, conditions: Gallstone, conditions: Gallstone Attack, conditions: Gastrointestinal Quality of Life Index, conditions: Probiotics, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: Ursodoxycholic acid group, interventions name: Bifidobacterium group, outcomesModule primaryOutcomes measure: The incidence of gallstones in bariatric surgery patients, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Shandong Linglong Yingcheng Hospital, status: RECRUITING, city: Yantai, state: Shandong, zip: 264000, country: China, contacts name: Xuan Qiu, MD, role: CONTACT, phone: 8618354280081, email: qiuxuan100@163.com, contacts name: Ni Wang, MD, role: CONTACT, phone: 8618705353551, email: wangni1989@163.com, geoPoint lat: 37.47649, lon: 121.44081, hasResults: False
protocolSection identificationModule nctId: NCT06287905, orgStudyIdInfo id: Soh-Med-23-02-24, briefTitle: A Comparative Study of Using Scorpion Antivenom Versus Scorpion Antivenom and Prazosin, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-01, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: Interventional study designed for the evaluation of characters and the outcome of scorpion sting patients will admit to Sohag University Hospitals in 2 randomized groups. The first group will receive scorpion antivenom only whether by the intravenous or the intramuscular route of administration. The second group will receive a combination of prazosin plus scorpion antivenom whether by the intravenous or the intramuscular route of administration. Both groups will receive proper first aid and supportive treatment, conditionsModule conditions: Morality, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: observational comparative, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Simple randomization, whoMasked: PARTICIPANT, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Prazosin Oral Tablet, outcomesModule primaryOutcomes measure: Mortality, secondaryOutcomes measure: Morbidity, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 70 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Meray Medhat Shokry Zaghary, status: RECRUITING, city: Sohag, zip: 82515, country: Egypt, contacts name: Meray M Shokry Zaghary, role: CONTACT, phone: +201028911003, email: drevanho2013@gmail.com, contacts name: Mai M Abd El Kader, role: CONTACT, phone: +201028911003, email: drevanho2013@gmail.com, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False
protocolSection identificationModule nctId: NCT06287892, orgStudyIdInfo id: AI-ECG-HCM, briefTitle: Diagnosis of HCM With AI-ECG, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, descriptionModule briefSummary: The study aims to establish a diagnostic model of hypertrophic cardiomyopathy with artificial intelligence-enhanced electrocardiogram., conditionsModule conditions: Hypertrophic Cardiomyopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 10000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Diagnosis of HCM with AI-ECG, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: 180 Fenglin Road, status: RECRUITING, city: Shanghai, zip: 200032, country: China, contacts name: Yixiu Liang, MD, role: CONTACT, phone: +8664041990, phoneExt: 612844, email: liang.yixiu@zs-hospital.sh.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06287879, orgStudyIdInfo id: 20231121, briefTitle: Function and Morphological Characteristics of Meibomian Gland in Patients With Renal Anemia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2024-12-20, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Zhongnan Hospital, class: OTHER, descriptionModule briefSummary: Renal anemia refers to anemia in which the absolute or relative production of erythropoietin (EPO) is insufficient due to various kidney diseases, and uremic toxins affect erythropoietin production and its lifespan. Common treatment drugs for renal anemia include erythropoietin EPO and Roxadustat (FG-4592).Medical history information was collected from patients with renal anemia who visited the ophthalmology department with dry eye symptoms.This study will help to determine the function and morphological characteristics of meibomian gland in patients with renal anemia, conditionsModule conditions: Dry Eye, conditions: MGD-Meibomian Gland Dysfunction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Dry eye examination, outcomesModule primaryOutcomes measure: Lacrimal river height, primaryOutcomes measure: tear break-up time, primaryOutcomes measure: tear-film lipid layer thickness, primaryOutcomes measure: meibomian glands two-dimensional digital infrared images, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhongnan Hospital of Wuhan University, status: RECRUITING, city: Wuhan, state: Hubei, zip: 430071, country: China, contacts name: Min Ke, Doctor, role: CONTACT, phone: +86-18672395959, email: keminyk@163.com, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06287866, orgStudyIdInfo id: 2099470, briefTitle: Pinch Grafting Versus Second Intention Wound Healing for Mohs Micrographic Surgery Defects on the Scalp, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: University of California, Davis, class: OTHER, descriptionModule briefSummary: Oftentimes, following surgery on the scalp, wounds are left to heal by themselves. This is called "second intention." Open wounds left to heal on the scalp often take 8 weeks or more to completely heal. We are investigating how second intention closure compares to another established reconstruction technique, called "pinch graft." In the pinch graft technique, we numb and then shave off a thin piece of skin (usually from the groin area) and place it in the wound bed it (also known as "grafting"), to encourage growth of new healthy skin. This study will compare time-to-healing in the second intention method versus the pinch graft method., conditionsModule conditions: Scarring, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, maskingDescription: Two blinded observers will record their scores independently using the POSAS instrument., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Pinch Graft, outcomesModule primaryOutcomes measure: Time to re-epithelialization, secondaryOutcomes measure: Observer Scar Assessment as measured by Patient Observer Scar Assessment Score (POSAS), secondaryOutcomes measure: Patient Scar Assessment as measured by Patient Observer Scar Assessment Score (POSAS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, Davis - Dermatology Department, status: RECRUITING, city: Sacramento, state: California, zip: 95816, country: United States, contacts name: John Robb, BS, role: CONTACT, phone: 916-551-2636, email: jmrobb@ucdavis.edu, contacts name: Daniel Eisen, MD, role: CONTACT, phone: 916-551-2611, email: dbeisen@ucdavis.edu, contacts name: Daniel Eisen, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Keemberly Kim, MD, role: SUB_INVESTIGATOR, contacts name: Ilana Breen, MD, role: SUB_INVESTIGATOR, geoPoint lat: 38.58157, lon: -121.4944, hasResults: False
protocolSection identificationModule nctId: NCT06287853, orgStudyIdInfo id: EMBODY-004, briefTitle: Tapestry Rotator Cuff Repair PMCF, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-30, primaryCompletionDateStruct date: 2028-06-30, completionDateStruct date: 2029-06-30, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Zimmer Biomet, class: INDUSTRY, descriptionModule briefSummary: The study design is a prospective, multi-center, single-arm, non-randomized, and noncontrolled post market clinical follow-up study involving orthopedic surgeons skilled in arthroscopic rotator cuff repair as determined by the Sponsor., conditionsModule conditions: Rotator Cuff Tears, conditions: Rotator Cuff Injuries, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 170, type: ESTIMATED, armsInterventionsModule interventions name: Tapestry Biointegrative Implant, outcomesModule primaryOutcomes measure: Re-tear rate after arthroscopic rotator cuff repair, secondaryOutcomes measure: The American Shoulder and Elbow Surgeons (ASES) Score, secondaryOutcomes measure: Constant-Murley Score (CMS), secondaryOutcomes measure: The Single Assessment Numeric Evaluation (SANE) Score, secondaryOutcomes measure: EQ-5D-5L (EuroQol), secondaryOutcomes measure: Return to Work/Activity, secondaryOutcomes measure: Patient Satisfaction, secondaryOutcomes measure: Adverse Event, secondaryOutcomes measure: MRI Sugaya Classification, secondaryOutcomes measure: MRI Goutallier Classification, eligibilityModule sex: ALL, minimumAge: 21 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06287814, orgStudyIdInfo id: RECHMPL23_0299, briefTitle: French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2028-10-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: University Hospital, Montpellier, class: OTHER, descriptionModule briefSummary: Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.FRENCH-MRD-CRC is the French study of the european GUIDE.MRD project., conditionsModule conditions: Colorectal Cancer, conditions: Stage III Colon Cancer, conditions: Minimal Residual Disease, conditions: Liquid Biopsy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Blood sample/lliquid biopsy, outcomesModule primaryOutcomes measure: 3-year disease-free survival (DFS), secondaryOutcomes measure: Sensitivity (Se) of the ctDNA diagnostics, secondaryOutcomes measure: Specificity (Sp) of the ctDNA diagnostics, secondaryOutcomes measure: Positive predictive value of the ctDNA diagnostics, secondaryOutcomes measure: Negative predictive value of the ctDNA diagnostics, secondaryOutcomes measure: Area under the curve of the ctDNA diagnostics, secondaryOutcomes measure: Time to clinical recurrence, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Time to molecular recurrence, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06287788, orgStudyIdInfo id: NFEC-2024-068, briefTitle: A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-10-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Nanfang Hospital, Southern Medical University, class: OTHER, descriptionModule briefSummary: The performance of the predictive models for severe oropharyngeal mucositis established using current oral mucosal contouring method was unsatisfactory in nasopharyngeal carcinoma (NPC). Whereas the predictive model of a mucosal contouring method based on swallowing-induced breakthrough pain exhibited better overall performance. The aim of this prospective, multicenter, observational study was to further explore the predictive efficacy of this mucosal delineation method for radiation-induced oropharyngeal mucositis in NPC., conditionsModule conditions: Radiation-induced Oropharyngeal Mucositis, conditions: Swallowing-induced Breakthrough Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 240, type: ESTIMATED, outcomesModule primaryOutcomes measure: The AUC of the predictive model, secondaryOutcomes measure: The accuracy, sensitivity, specificity, positive predictive value, negative predictive value and F1 score of the predictive model, secondaryOutcomes measure: The important predictors of severe oropharyngeal mucositis in the predictive model, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Southern Medical University, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510515, country: China, contacts name: Jian Guan, Ph.D., role: CONTACT, phone: 86+13632102247, email: guanjian5461@163.com, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06287749, orgStudyIdInfo id: RECHMPL23_0298, briefTitle: French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2028-10-31, completionDateStruct date: 2028-10-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: University Hospital, Montpellier, class: OTHER, descriptionModule briefSummary: The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after1. curative-intended surgery and2. adjuvant chemotherapy.FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project, conditionsModule conditions: Pancreatic Cancer Resectable, conditions: Pancreatic Ductal Adenocarcinoma, conditions: Minimal Residual Disease, conditions: Liquid Biopsy, conditions: ctDNA, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 37, type: ESTIMATED, armsInterventionsModule interventions name: Blood sample/Liquid Biopsy, outcomesModule primaryOutcomes measure: 3-year Disease-free survival (DFS), secondaryOutcomes measure: Sensitivity (Se) of the ctDNA diagnostics, secondaryOutcomes measure: Specificity (Sp) of the ctDNA diagnostics, secondaryOutcomes measure: Positive predictive value of the ctDNA diagnostics, secondaryOutcomes measure: Negative predictive value of the ctDNA diagnostics, secondaryOutcomes measure: Are Under the Curve of the ctDNA diagnostics, secondaryOutcomes measure: Time to clinical recurrence, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Time to molecular recurrence, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False